Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 78.67% is 65% above its 5-year average of 47.74%, near the high end of its 5-year range (-531.37%–93.30%).
5.71% below its 12-month average of 83.43%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 93.30%.
GROSS MARGIN
78.67%
GROSS MARGIN AVG TTM
83.43%
GROSS MARGIN AVG 3Y
81.09%
GROSS MARGIN AVG 5Y
47.74%
GROSS MARGIN AVG 10Y
49.60%
GROSS MARGIN AVG 15Y
13.53%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-5.71%
CURRENT VS 3Y AVG
-2.98%
CURRENT VS 5Y AVG
+64.78%
CURRENT VS 10Y AVG
+58.62%
CURRENT VS 15Y AVG
+481.52%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.92%
median of 605 covered companies
CURRENT VS SECTOR MEDIAN
+83.29%
vs the sector median at left
Agios Pharmaceuticals, Inc.
Market Cap
$1.86B
Gross Margin
78.67%
TTM Avg
83.43%
3Y Avg
81.09%
5Y Avg
47.74%
Market Cap
$1.84B
Gross Margin
9.22%
TTM Avg
11.32%
3Y Avg
13.89%
5Y Avg
14.07%
Market Cap
$1.89B
Gross Margin
64.48%
TTM Avg
64.91%
3Y Avg
63.02%
5Y Avg
55.66%
Market Cap
$1.82B
Gross Margin
72.90%
TTM Avg
70.08%
3Y Avg
67.68%
5Y Avg
66.96%
Market Cap
$1.79B
Gross Margin
-319.36%
TTM Avg
-798.46%
3Y Avg
-813.46%
5Y Avg
-704.28%
Market Cap
$1.93B
Gross Margin
70.49%
TTM Avg
67.64%
3Y Avg
66.50%
5Y Avg
65.90%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. (AGIO) | $1.86B | 78.67% | 83.43% | 81.09% | 47.74% |
| Novavax, Inc. (NVAX)vs › | $1.86B | 93.67% | 81.97% | 61.43% | 74.28% |
| Astrana Health, Inc. (ASTH)vs › | $1.84B | 9.22% | 11.32% | 13.89% | 14.07% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 64.48% | 64.91% | 63.02% | 55.66% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 72.90% | 70.08% | 67.68% | 66.96% |
| Azenta, Inc. (AZTA)vs › | $1.91B | 44.05% | 44.96% | 41.63% | 40.93% |
| Novocure Ltd (NVCR)vs › | $1.81B | 76.13% | 75.94% | 76.33% | 77.05% |
| Absci Corporation (ABSI)vs › | $1.79B | -319.36% | -798.46% | -813.46% | -704.28% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.93B | 70.49% | 67.64% | 66.50% | 65.90% |
| Immunome, Inc. (IMNM)vs › | $1.95B | 57.43% | 78.72% | 64.36% | 42.91% |
Gross Margin
78.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 93.30% |
| 2026-03-31 | 87.07% |
| 2025-12-31 | 84.25% |
| 2025-09-30 | 76.30% |
| 2025-06-30 | 76.23% |
| 2025-03-31 | 72.92% |
| 2024-12-31 | 88.26% |
| 2024-09-30 | 91.27% |
| 2024-06-30 | 64.16% |
| 2024-03-31 | 75.88% |
| 2023-12-31 | 72.00% |
| 2023-09-30 | 91.44% |
| 2023-06-30 | 17.01% |
| 2023-03-31 | 11.71% |
| 2022-12-31 | -11.14% |
| 2022-09-30 | -42.52% |
| 2022-06-30 | 6.68% |
| 2022-03-31 | -531.37% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 97.82% |
| 2020-09-30 | 98.16% |
| 2020-06-30 | 98.19% |
| 2020-03-31 | 99.39% |
| 2019-12-31 | 99.19% |
| 2019-09-30 | 98.49% |
| 2019-06-30 | 98.84% |
| 2019-03-31 | 98.90% |
| 2018-12-31 | 97.66% |
| 2018-09-30 | 95.43% |
| 2018-06-30 | -114.60% |
| 2018-03-31 | -792.76% |
| 2017-12-31 | -688.00% |
| 2017-09-30 | -541.99% |
| 2017-06-30 | -603.47% |
| 2017-03-31 | -496.99% |
| 2016-12-31 | -185.58% |
| 2016-09-30 | -574.94% |
| 2016-06-30 | -628.06% |
| 2016-03-31 | -40.78% |
| 2015-12-31 | -493.97% |
| 2015-09-30 | -557.45% |
| 2015-06-30 | -175.54% |
| 2015-03-31 | 5.14% |
| 2014-12-31 | -138.19% |
| 2014-09-30 | 24.70% |
| 2014-06-30 | -168.41% |
| 2014-03-31 | -106.96% |
| 2013-12-31 | -126.56% |
| 2013-09-30 | -136.17% |
| 2013-06-30 | -106.73% |
| 2013-03-31 | -82.87% |
| 2012-12-31 | -78.69% |
| 2012-09-30 | -56.32% |
| 2012-06-30 | 100.00% |
| 2012-03-31 | 100.00% |
